iifl-logo

Mangalam Drugs and Organics Ltd Directors Report

Add as a Preferred Source on Google
₹28.56
(0.60%)
Nov 19, 2026|03:50:05 PM

Mangalam Drugs and Organics Ltd Share Price directors Report

To,


The Members of


Mangalam Drugs & Organics Limited (Company)

Your directors (hereinafter referred to as the Board) have pleasure in presenting the 53rd (Fifty Third) Annual Report of the Company including Audited Financial Statements for the Financial Year ended March 31, 2026.

1. FINANCIALS:

A. FINANCIAL RESULTS AND HIGHLIGHTS OF PERFORMANCE:

The Standalone Financial Performance of the Company for the year ended March 31, 2026, in comparison with previous year is summarized below:

Standalone Financial Performance

(Figures – Rs. In Lakhs)

Particulars March 31, 2026 March 31, 2025
Operational Income & Other Income 23,289.58 31,872.77
Total Expenses including Interest Expense and Depreciation and Amortization Expense 28,088.32 31,373.83
Profit before exceptional items and tax (4,798.74) 498.94
Prior period items NIL NIL
Exceptional Items NIL NIL
Provision for diminution in the value of investments NIL NIL
Profit before tax (PBT) (4,798.74) 498.94
Tax Expense (417.32) (193.49)
Profit after tax (PAT) (4,381.42) 692.43
Total comprehensive income (4,426.66) 630.86
Earnings Per Share (In Rs.) (Basic/Diluted) (27.68) 4.37

Consolidated Financial Performance

(Figures – Rs. In Lakhs)

Particulars March 31, 2026 March 31, 2025
Operational & Other Income 23,289.58 31,873.28
Total Expenses including Interest Expense and Depreciation and Amortization Expense 28,146.72 31,394.70
Profit before exceptional items and tax (4,857.14) 478.58
Prior period items NIL NIL
Exceptional Items NIL NIL
Provision for diminution in the value of investments NIL NIL
Profit before tax (PBT) (4,857.14) 478.58
Tax Expense (417.13) (193.49)
Profit after tax (PAT) (4,440.00) 672.07
Total comprehensive income (4,485.24) 1,318.62
Earnings Per Share (In Rs.) (Basic/Diluted) (28.05) 4.25

The Company Mangalam Laboratories Private Limited has become wholly owned subsidiary of the Company on September 30, 2023, and therefore the consolidation of financials is applicable from the Financial Year 2024.

B. OPERATIONS OF THE COMPANY / COMPANY PERFORMANCE

During the Financial Year under report, the Company registered a total revenue from operations of Rs. 23,213.27 Lakhs as against Rs. 31,757.60 Lakhs in the previous year & registered an economic decline of 26.90% over the previous year. The operational performance has resulted into increased loss of Rs. (4,381.42) Lakhs as compared to the previous year of Rs. 692.43 Lakhs.

Further, there has been no change in business during the year under review.

C. HIT ON PAT AND FUTURE OUTLOOK

During the Financial Year 2025-26, the PAT Margin of the Company was declined because of following reasons numbered below:

The financial stress faced by Mangalam Drugs and Organics Limited ("Mangalam") is not structural or operational in nature, but has arisen due to extraordinary external factors impacting the global public-health pharmaceutical procurement ecosystem over the last two years. Mangalam is primarily engaged in the manufacture of WHO-prequalified anti-malarial and other tropical disease APIs, a segment where procurement is largely undertaken through institutional and donor-funded international tenders, rather than through open commercial markets.

A significant portion of Mangalams revenue—approximately 65%–70%—is dependent on procurement tenders floated by global health agencies such as the Global Fund, UNICEF, UNITAID, and USAID. These agencies procure medicines for malaria, tuberculosis, and HIV treatment programs across developing and under-developed countries. While the underlying medical demand for these therapies has remained intact, the funding mechanism for procurement has been severely disrupted. Over the past two years, international donor funding has been adversely affected due to geopolitical and macroeconomic developments, including global conflicts, fiscal pressures in developed economies, and re-prioritization of sovereign budgets.

These factors resulted in reduced allocations to global health programs, directly impacting the volume and timing of tenders issued by procurement agencies. The situation was further aggravated by the complete disbandment of USAID in December, which had historically been a major contributor to global healthcare funding and a key donor to the Global Fund. The withdrawal of USAID funding led to funding gaps and deferment of procurement decisions, causing a sharp decline in tender issuance across malaria and tropical disease segments. This had a cascading effect on API manufacturers whose business models are aligned to donor-funded supply chains.

As a consequence of the above, Mangalam experienced order deferrals, reduced tender participation, and temporary underutilization of manufacturing capacity, leading to stress on cash flows and working capital cycles. It is pertinent to note that this is the first such downturn faced by the Company in over 50 years of operations, underscoring the exceptional and non-recurring nature of the event. The stress is a temporary disruption in global funding and procurement cycles, rather than any decline in product relevance, regulatory standing, manufacturing capability, or market acceptance of Mangalams APIs. The Company continues to retain its WHO approvals and long-standing relationships with international formulators, and the stress has arisen solely due to external funding-linked constraints beyond the control of the Company.

The Company has taken various steps to improve PAT margins for the coming Financial Years. Key initiatives undertaken by the management include:

  • Rationalization and optimization of operating expenses across the organization, including strict control over discretionary expenditures such as travel, conveyance, and other administrative costs.
  • Improvement of cash flows and working capital management through focused collection efforts and customer-specific incentive programs.
  • Review and optimization of manpower costs through efficient workforce planning and redeployment of resources, while ensuring continuity of critical operations.
  • Re-alignment of the product portfolio by reducing production of products with lower contribution margins and increasing focus on products that offer better profitability and sustainable returns.
  • Strengthening inventory management practices by reducing excess inventory levels, improving inventory turnover, and implementing tighter controls over procurement and stock holding.

D. SHARE CAPITAL

Authorized Share Capital:

During the year there has been no change in the Authorized Share Capital of the Company. The Companys Authorized Share Capital is Rs. 30,00,00,000/- (Rupees Thirty Crores only) comprising of 3,00,00,000 (Three Crore) Equity Shares of Rs. 10/- each.

Issued, Subscribed and Paid-Up Share Capital of the Company:

The Companys paid-up capital is Rs. 15,82,82,480/- (Fifteen Crore Eighty-Two Lakhs Eighty-Two Thousand Four Hundred and Eighty) comprising of 1,58,28,248 (One Crore Fifty-Eight Lakhs Twenty-Eight Thousand Two Hundred and Forty-Eight Only) Equity Shares of Rs. 10/- each fully paid up. The Companys Equity shares are listed on the National Stock Exchange of India Ltd (NSE) and Bombay Stock Exchange Ltd (BSE).

There has been no change in paid up share capital of the Company during the Financial Year under review as the Company has not:

  • Issued Shares on Rights basis as per provisions of Section 62 of Companies Act, 2013 (The Act).
  • Issued Shares on Private Placement basis as per provisions of Section 42 of the Act.
  • Issued Bonus Shares as per provisions of Section 63 of the Act.
  • Issued any Sweat Equity Shares as per provisions of Section 54 (1) (d) of the Act.
  • Issued any equity shares under Employees Stock Option Scheme as per provisions of Section 62 (1) (b) of the Act; and
  • Bought back any shares as per provisions of Section 68 of the Act.

E. DIVIDEND

The Company considering the losses in financial year under review, your directors have not recommended any dividend on Equity Shares for the Financial Year 2025-26.

F. TRANSFER TO RESERVES

The Company has not transferred any amount to Reserves.

G. UNPAID DIVIDEND & IEPF

The Company is not required to transfer any amount to the Investor Education & Protection Fund (IEPF) and does not have an unclaimed dividend which remains to be transferred to Unpaid Dividend Account.

H. PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS

Pursuant to the provisions of Section 186 of the Companies Act, 2013, read with the Companies (Meetings of Board and its Powers) Rules, 2014 as amended from time to time (including any amendment thereto or re-enactment thereof for the time being in force), the Loans, guarantees and investments covered under Section 186 of the Companies Act, 2013 forming part of Financial Statements provided in this Annual Report.

I. DEPOSITS

During the year under review, the Company has not accepted or renewed any amount falling within the purview of provisions of Section 73 of the Companies Act 2013 (the Act) read with the Companies (Acceptance of Deposit) Rules, 2014. Hence, the requirement for furnishing of details relating to deposits covered under Chapter V of the Act or the details of deposits which are not in compliance with Chapter V of the Act is not applicable.

J. LOAN FROM DIRECTORS

During the year under review, the Company has not taken any loan from its directors and their relatives.

2. REPORT ON PERFORMANCE OF SUBSIDIARIES, ASSOCIATIONS AND JOINT VENTURE COMPANIES

During the Financial Year under review, the Company has (1) one Unlisted Wholly Owned Subsidiary, Mangalam Laboratories Private Limited, and has no Associate and Joint Venture.

  • Report on Subsidiary of Company: Pursuant to the provisions of Section 129 (3) of the Companies Act, 2013, a statement containing salient features of the Financial Statements, highlights of the performance of the subsidiary are furnished in Form AOC-1 is annexed hereto and marked as Annexure-A and forms part of this Report.
  • Financial Statements of Subsidiary of Company: The details regarding the contribution of the subsidiary to the overall performance of the Company during the Financial Year have been included in the Consolidated Financial Statements of the Company for the Financial Year 2025-26 which is provided in this Annual Report.
  • Further, the Audited Standalone Financial Statements of the Mangalam Laboratories Private Limited, a Wholly Owned Subsidiary of the Company is available on the website of the Company at https://www.mangalamdrugs.com/investors/. Members interested in obtaining a copy of the Audited Standalone Financial Statements of the Mangalam Laboratories Private Limited, a Wholly Owned Subsidiary of the Company may write to the Company at cs@mangalamdrugs.com
  • Policy for Material Subsidiary: In terms of Regulation 16 (1) (c) of Listing Regulations and Companys Policy for Determining Material Subsidiary, Mangalam Laboratories Private Limited, a Wholly Owned Subsidiary, make it everywhere of the Company is not a material subsidiary of your Company.
  • Independent Director of Subsidiary of Company: Further, in terms of explanation to Regulation 24(1) of the Listing Regulations, the requirement of appointing an Independent Director of the Company on the board of directors of Mangalam Laboratories Private Limited, a Wholly Owned Subsidiary of the Company is currently not applicable.
  • Functions of Audit Committee for Subsidiary of Company: The Audit Committee reviews the investments made by Mangalam Laboratories Private Limited and the statement of all significant transactions and arrangements entered by Mangalam Laboratories Private Limited, a Wholly Owned Subsidiary of the Company. Also, the minutes of board meetings of Mangalam Laboratories Private Limited and detailed presentations on business performance of Mangalam Laboratories Private Limited, a Wholly Owned Subsidiary of the Company, are placed before the Board.
  • Change in Nature of Business of Subsidiary of Company: During the Financial Year under review, there has been no change in the nature of business of the Mangalam Laboratories Private Limited, a Wholly Owned Subsidiary of the Company and there were no additions/deletions in the number of Associate Companies, Joint Venture, and subsidiary of your Company as on March 31, 2026.
  • Remuneration to Director of Subsidiary Company: There is no remuneration drawn by of Wholly Owned Subsidiary of the Company from the Company.
  • Loan to Subsidiary: During the Financial Year under review, the Company has not provided any loan to its Mangalam Laboratories Private Limited, a Wholly Owned Subsidiary of the Company.
  • Secretarial Audit of Subsidiary of Company: In terms of Regulation 24A of the Listing Regulations, the Secretarial Audit of Mangalam Laboratories Private Limited, a Wholly Owned Subsidiary of the Company, is not applicable.

(Note: The source page contains a duplicated/repeated fragment of the Loan to Subsidiary and Secretarial Audit paragraphs; content is identical.)

3. REMUNERATION / COMMISSION DRAWN FROM HOLDING / SUBSIDIARY COMPANY

The Company does not have Holding Company and hence the said clause is not applicable. The details pertaining to subsidiary covered herein above.

4. CONSOLIDATED FINANCIAL STATEMENTS

The Consolidated Financial Statements of the Company for Financial Year 2025-26 is attached to this report.

Further, Your Company does not have investment in any Associate / Joint Venture Company as on March 31, 2026.

5. DISCLOSURE OF LOANS AND ADVANCES IN NATURE OF LOAN TO SUBSIDIARIES AND ASSOCIATE OF THE COMPANY

The Company does not have associate as on March 31, 2026.

Further, the company has not provided any loans and advances in nature of Loan to its Wholly Owned Subsidiary i.e., Mangalam Laboratories Private Limited.

6. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNINGS AND OUTGO

A statement containing the necessary information for conservation of energy, technology absorption and foreign exchange earnings and outgo stipulated under section 134 (3) (m) of the Act read with rule 8 of Companies (Accounts) Rules, 2014 is annexed to the Annual Report as Annexure-B.

7. RELATED PARTY TRANSACTIONS

A. THE PARTICULARS OF CONTRACTS OR ARRANGEMENTS WITH RELATED PARTIES:

All related party transactions that were entered into during the Financial Year were on an arms length basis and were in the ordinary course of business as part of Companys philosophy of adhering to highest ethical standards, transparency and accountability. These transactions are not likely to have any conflict with the Companys interest.

All Related Party Transactions up to March 31, 2026 were placed before the Audit Committee and the Board for their approval. Also, prior omnibus approval of the Audit Committee was obtained for Related Party Transactions for the Financial Year 2025-26. The transactions entered pursuant to the omnibus approval so granted were audited and a statement giving details of all related party transactions was placed before the Audit Committee for its review on a quarterly basis. The particulars of transactions between the Company and its related parties as per the Accounting Standard-18 are set out in Notes to Accounts in the Annual Report. In line with the provisions of the Companies Act, 2013 and the Listing Regulations, the Board has approved a policy on related party transactions. An abridged policy on related party transactions has been placed on the Companys website at: https://www.mangalamdrugs.com/wp-content/uploads/2022/08/Policy-on-Related-Party-Transaction.MDOL.pdf

8. MATTERS RELATED TO INDEPENDENT DIRECTORS

A. DECLARATIONS BY INDEPENDENT DIRECTORS:

The Independent Directors have submitted the Declaration of Independence, as required pursuant to section 149 (7) of the Companies Act, 2013 and Regulation 16 and 25 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 stating that they meet the criteria of independence as provided in sub-section (6). There has been no change in the circumstances, which has affected their status as independent director. Further, they also declared that they have complied with Rule 6 (1) of the Companies (Appointment and Qualifications of Directors) Rules, 2014 with respect to the inclusion of name in the data bank created by the Indian Institute of Corporate Affairs.

B. EVALUATION BY INDEPENDENT DIRECTOR:

Pursuant to the provisions of the Companies Act, 2013 and Regulation 17 (10) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, at the separate meeting of Independent Directors held on August 07, 2025, the performance of non-independent directors, performance of the Board as a whole and performance of the Chairman was evaluated, taking into account the views of executive director along with performance evaluation of committees. The evaluation mechanism has been explained in the Corporate Governance Report.

C. OPINION OF BOARD OF DIRECTORS PERTAINING TO INDEPENDENT DIRECTORS OF THE COMPANY:

In the opinion of the Board of Directors, all the Independent Directors on the Board of the Company are independent of the management and complies with criteria of Independent Director as submitted by them under Companies Act, 2013 and under Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. They possess integrity, expertise and also have vast experience which is necessary or suitable to be the Director of the Company. Further, they have no pecuniary relationship other than sitting fee for attending meetings of the Company.

9. MATTERS RELATING TO BOARD OF DIRECTORS

A. MEETING OF BOARD OF DIRECTORS OF THE COMPANY DURING THE FINANCIAL YEAR 2025-2026:

During the year under review, the Board met 8 (Eight) Board Meetings were convened and held on April 11, 2025, May 17, 2025, August 07, 2025, September 05, 2025, November 20, 2025, January 15, 2026, February 06, 2026, and March 26, 2026, in accordance with the provisions of the Companies Act, 2013 to discuss and decide on various business strategies, policies and other issues. The intervening gap between any two Meetings was not more than the period prescribed by the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. The Company has complied with the applicable Secretarial Standards in respect of all the above-Board Meetings.

The detailed composition of Board of Directors and requisite details are given in the Corporate Governance Report.

B. FORMAL ANNUAL EVALUATION OF THE PERFORMANCE OF BOARD, ITS COMMITTEES AND DIRECTORS:

The Board of Directors has adopted a formal mechanism for evaluating various aspects of the Boards functioning its performance and as well as that of its committee i.e., Audit, Nomination and Remuneration, Stakeholders Relationship and individual directors. The exercise was carried out through a structured evaluation process covering various aspects of the Boards functioning such as composition of the Board and Committees, experience and competencies, performance of specific duties and obligations, governance issues etc. Separate exercise was carried out to evaluate the performance of Individual Directors who was evaluated on parameters such as attendance, contribution at the meetings and otherwise, independent judgment, safeguarding of minority shareholders interest. The Board of Directors expressed their satisfaction with the evaluation process.

C. BOARD DIVERSITY

The Company recognises and embraces the importance of a diverse Board in its success. The Board has adopted the Board Diversity Policy which sets out with an approach to diversify the Board of Directors. The Board Diversity Policy is available on the Companys website: https://www.mangalamdrugs.com/wp-content/uploads/2022/08/Policy-on-Board-Diversity.pdf.

10. APPOINTMENT, RE-APPOINTMENT AND RESIGNATION OF DIRECTORS DURING THE YEAR 2025-26:

The Board of Directors of the Company is led by the Executive Chairman and comprises of four other Directors as on March 31, 2026, including two Independent Directors which includes one Woman Director as required under Section 149 (1) of the Companies Act, 2013. The composition of the Board is in conformity with the provisions of the Companies Act 2013 and the SEBI (Listing Obligations and Disclosure Requirements) 2015.

  • Appointment: No appointment of any director was made during the Financial Year under review.
  • Re-appointment: Re-appointment of Shri Praveen Saxena as an Independent Director of the Company for 5 years for 2 consecutive terms w.e.f. 21st March, 2026 till 20th March, 2031.
  • Resignation: Shri Rukmesh Dhandhania, Independent Director resigned from the Company w.e.f. January 16, 2026.
  • Change in Designation: No Change in designation of any director was made during the Financial Year under review.
  • Retire by Rotation: Shri Govardhan Muridhar Dhoot (DIN: 01240086) is retiring by rotation in this 53rd Annual General Meeting and is offering himself for reappointment.

11. APPOINTMENT, RE-APPOINTMENT AND RESIGNATION OF KEY MANAGERIAL PERSONS DURING THE YEAR 2025-26:

During the Financial Year under review, there was change in composition of Key Managerial Personnel of the Company. The details of which are follows as below:

Shri Ajay Samant, Chief Financial Officer of the Company resigned on January 31st, 2026 and Shri Jeevan Dalvi was appointed as new Chief Financial Officer w.e.f. February 06th, 2026.

Further, Smt. Anuradha Pandey, Company Secretary and Compliance Officer resigned from the Company with effect from March 29th, 2026 and Smt. Shweta Patel was appointed as new Company Secretary and Compliance Officer w.e.f. April 01st, 2026.

12. COMMITTEES OF BOARD OF DIRECTORS OF THE COMPANY:

As on the date of approval of Directors Report, following are the Committees of Board of Directors of the Company constituted under Companies Act, 2013, Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013, Companies Act 2013 and applicable regulations of Securities and Exchange Board of India (SEBI Regulations). Composition of the following Committees are also hosted on the website of the Company at https://www.mangalamdrugs.com/wp-content/uploads/2022/08/Terms-of-Reference-of-all-Committees_MDOL.pdf.

A. AUDIT COMMITTEE (AC)
B. NOMINATION AND REMUNERATION COMMITTEE (NRC)
C. STAKEHOLDERS RELATIONSHIP COMMITTEE (SRC)
D. CORPORATE SOCIAL RESPONSIBILITY COMMITTEE (CSRC)
E. INTERNAL COMPLAINT COMMITTEE FOR PREVENTION AND PROHIBITION OF SEXUAL HARASSMENT OF WOMAN AT WORKPLACE

The constitutions, composition, terms of reference, details of meetings and attendance of members of afore-mentioned Committees have been mentioned in the Corporate Governance Report.

Further, the Board of Directors has also formed an Executive Committee (EC), which is a non-mandatory committee and delegated power to EC members to consider and approve day-to-day business matters. The decisions taken by the EC members are considered on record by the Board in their meetings

VIGIL MECHANISM / WHISTLE BLOWER POLICY:

In accordance with the provisions of Section 177 (9) and (10) of the Companies Act, 2013 read with Rule 7 of the Companies (Meetings of Board and its Powers) Rules, 2014, and Regulation 22 of SEBI (LODR) Regulations 2015 the Company already has in place Vigil Mechanism Policy" (Whistle Blower Policy) for Directors and employees of the Company to provide a mechanism which ensures adequate safeguards to employees and Directors from any financial statements and reports, etc.

The employees of the Company have the right/option to report their concern/grievance to the Chairman of the Audit Committee. The Company is committed to adhere to the highest standards of ethical, moral and legal conduct of business operations. The policy is also available on the Companys website at https://www.mangalamdrugs.com/wp-content/uploads/2022/08/Whistle-Blower-Policy.pdf

G. RISK MANAGEMENT POLICY:

The Company is not required to constitute Risk Management Committee pursuant to Regulation 21 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. However, the Board of Director in pursuance to Regulation 17 (9) (b) has laid down risk management plan to deal with the risks that might become threat to the existence of the Company and subsequently affect the going concern status of the Company. The Risks are classified in different categories such as Financial, Operational, Legal and Strategic risks. These risks are reviewed from time to time and controls are put in place with specific responsibility of the concerned officers of the Company. Further, a separate section on probable risks and their management is provided in the Management Discussion and Analysis (MD&A) Report. The Company has in place a Policy on Risk Management for systematic approach to control risks.

13. AUDITORS & REPORTS:

A. STATUTORY AUDITORS OF THE COMPANY:

M/s. V. S. Somani & Co., Chartered Accountants (FRN: 117589W) will complete their term as Statutory Auditors at the conclusion of the 53rd AGM. The Board of Directors places on record its deep appreciation for their professional services and contribution to the Company during their tenure. Accordingly, based on the recommendation of the Audit Committee, the Board of Directors has recommended the appointment and fixing of remuneration of M/s. S.N. Nanda and Co., Chartered Accountants (Firm Registration No. 000685N), as the Statutory Auditors of the Company for a term of five consecutive years, commencing from the conclusion of the 53rd AGM up to the conclusion of the 58th AGM of the Company, subject to approval of the shareholders.

M/s. S.N. Nanda and Co., have confirmed their eligibility and that they satisfy the criteria prescribed under Section 141 of the Companies Act, 2013, and that their appointment, if approved, will be in accordance with the applicable provisions of the Act and the rules made thereunder. They have also confirmed that they have subjected themselves to the peer review process of the Institute of Chartered Accountants of India ("ICAI") and hold a valid certificate issued by the "Peer Review Board of ICAI".

Explanations or Comments on the Qualification, Reservation or Adverse Remark or Disclaimer made by the Auditor in his report for the year ended March 31st, 2026:

The auditor has not expressed any qualification or adverse remark in his report.

B. SECRETARIAL AUDITORS OF THE COMPANY:

Based on the recommendation of Board of Directors and Audit Committee M/s. L. N. Joshi & Co., Practising Company Secretary - C.P. 4216, is being appointed as the Secretarial Auditor of the Company for a term of five (5) consecutive years, commencing from the conclusion of the 53rd Annual General Meeting until the conclusion of the 58th Annual General Meeting of the Company, subject to approval from members in place of resigning secretarial auditor M/s Ragini Chokshi & Co. - FRN No. 92897. The Board of Directors places on record its deep appreciation for their professional services and contribution to the Company during their tenure.

M/s. L. N. Joshi & Co. is a firm of Practicing Company Secretaries having extensive experience in corporate laws, securities laws, and secretarial audit. The firm has conveyed its consent to act as the Secretarial Auditor of the Company and has confirmed its eligibility and independence in accordance with the applicable provisions of the Companies Act, 2013 and the rules made thereunder.

As per Section 204 of the Act read with Rule 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 the Company had appointed M/s Ragini Chokshi & Co., - Practicing Company Secretaries to conduct Secretarial Audit for the financial year 2025-26. The Secretarial Audit Report in form MR.3 for the Financial Year ended March 31, 2026, is attached herewith as Annexure-C to this report.

The Management reply on observations marked out by Secretarial Auditor is given below:

Observations/Remarks of the Secretarial Auditor Management Reply
Enhancements in Structured Digital Database (SDD) software as per requirement of SEBI (LODR), 2015. The Company has initiated the necessary developments and enhancements in the SDD software.
Inadequate composition of the Board/Committees from 16 January 2026 to 31 March 2026 as per the requirements of the SEBI (LODR), 2015. The Company is in the process of taking necessary steps to ensure that the composition of the Board and its Committees is adequate.
Delay in filing of Outcome of Board Meeting dt: 15/01/2026 within 30 minutes of closure of Board Meeting as per Regulation 30 Schedule III of SEBI (LODR), 2015. Due to an inadvertent oversight, there was a delay in filing the outcome of the Board Meeting.
Delay in filing of Outcome of Board Meeting for the quarter ended 30/09/2025 Due to unavoidable circumstances, the Company was unable to finalize the financial results for the quarter within time, resulting in a delay.
Non-filing of MGT-14 for approval of Boards Report, Management Discussion and Analysis Report, Corporate Governance Report for board meeting 05/09/2025. However, as on the date of this Report, the requisite compliance has been completed and the relevant filing has been made with the Registrar of Companies.

Regulation 24 (A) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 inter-alia requires every listed company to annex with its Boards report, a Secretarial Annual Compliance Report given by a Company Secretary in practice, in the prescribed form. The Secretarial Annual Compliance Report given by Ragini Chokshi & Co., - Practicing Company Secretaries for the Financial Year 2025-26 is annexed hereto and marked as Annexure-D.

C. COST AUDITORS OF THE COMPANY:

As per Section 148 of the Act read with rules framed thereunder, Rampurawala Mohammed A & Co., Cost Accountants, (Membership No. 32100) was appointed as Cost Auditors for the Financial Year 2025-26 to conduct cost audit of the accounts maintained by the Company in respect of the Bulk Drugs as prescribed under the applicable Cost Audit Rules.

Further, Rampurawala Mohammed A & Co., Cost Accountants have certified that their appointment is within the limits of Section 141 (3) (g) of the Companies Act, 2013 and that they are not disqualified from being re-appointed within the meaning of the said Act. The remuneration of Cost Auditors has been approved by the Board of Directors on the recommendation of the Audit Committee.

D. REPORTING OF FRAUDS BY STATUTORY AUDITORS UNDER SECTION 143 (12) OF THE COMPANIES ACT, 2013:

During the Financial Year under review, the Statutory Auditors have not reported any incident of fraud to the Audit Committee or to the Board of Directors of the Company.

E. INTERNAL AUDIT AND INTERNAL CONTROL SYSTEMS:

The Company has an internal control system for its business processes across departments to ensure efficient operations, compliance with internal policies, applicable laws and regulations, protection of resources and assets and appropriate reporting of financial transactions.

The Company has an Internal Audit function which is empowered to examine the adequacy and compliance with policies, plans and statutory requirements. It comprises of experienced professionals who conduct regular audits across the Companys operations. The Company has appointed M/s. Bipin Zavar & Associates, Chartered Accountants, as Internal Auditor of the Company for the Financial Year 2025-26, who review the various functions of the Company thoroughly and report to the Audit Committee. During the year under review, the Risk Management Committee of the Company had reviewed the new requirement of Internal Control over Financial Reporting ("ICOFR") and finalized the detailed analysis of key processes, and these were presented for review by the Statutory Auditors. The Statutory Auditors have submitted their report on the Internal Financial Controls which forms an integral part of this Report. No significant events had come to notice during the year under review that have materially affected or are reasonably likely to materially affect IFC. Considering the business operations of the Company, the Management believes that the IFC and other financial reporting were effective and adequate during the year under review.

Further, the adequacy of the same has been reported by the Statutory Auditors of your Company in their report as required under the Companies (Auditors Report) Order, 2020.

14. EXTRACT OF ANNUAL RETURN:

Pursuant to the provisions of Section 134 (3) (a) of the Companies Act, 2013, the draft Annual Return for the Financial Year ended March 31, 2026 made under the provisions of Section 92 (3) of the Act is made available on the website of the Company and can be accessed at: https://www.mangalamdrugs.com/investors/

15. MANAGEMENT DISCUSSION AND ANALYSIS REPORT:

The Management Discussion and Analysis Report on the operations of the Company as required pursuant to Part B of Schedule V of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is annexed hereto and marked as Annexure-E and forms part of this Report.

16. PARTICULARS OF EMPLOYEES AND RELATED DISCLOSURES:

In terms of the provisions of Section 197 (12) of the Act read with sub-rules 2 & 3 of Rule 5 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, as amended, the information required under Section 197 of the Act read with rule 5 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 are given in Annexure-F.

17. ANNUAL REPORT ON CSR ACTIVITIES / INITIATIVES FOR FINANCIAL YEAR 2025-26:

The Company is not required to provide Annual Report on Corporate Social Responsibility activities / Initiatives for Financial Year 2025-26 as the Company does not fall under the criteria provided under section 135 (1) of Companies Act, 2013.

18. CORPORATE GOVERNANCE REPORT:

The Corporate Governance Report pursuant to Regulations 17 to 27, clauses (b) to (i) of Regulation 46 (2) and Para C, D and E of Schedule V of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is annexed hereto and marked as Annexure-G and forms part of this Report.

19. DETAILS OF PENDING PROCEEDINGS UNDER THE INSOLVENCY AND BANKRUPTCY CODE, 2016 (31 OF 2016) DURING THE YEAR ALONG-WITH THEIR STATUS AS THE END OF THE FINANCIAL YEAR:

During the period under review, this clause is not applicable.

20. THE DETAILS OF DIFFERENCE BETWEEN AMOUNT OF VALUATION DONE AT TIME OF ONE-TIME SETTLEMENT AND THE VALUATION DONE WHILE TAKING LOAN FROM THE BANK OR FINANCIAL INSTITUTIONS ALONG WITH THE REASON THEREOF:

During the period under review, this clause is not applicable.

21. MATERIAL CHANGES AND COMMITMENTS AFFECTING FINANCIAL POSITION BETWEEN THE END OF THE FINANCIAL YEAR AND DATE OF THE REPORT:

Save and except as discussed in the Annual Report, no material changes have occurred and no commitments were given by the Company which affects the financial position between the end of financial year to which the financial statements relate and the date of this report.

22. LEGAL AND REGULATORY:

Pursuant to the Compliance with laws and regulations is an essential part of your Companys business operations. We are subject to laws and regulations in diverse areas as trademarks, copyright, patents, competition, employee health and safety, the environment, corporate governance, listing and disclosure, employment and taxes.

Frequent changes in legal and regulatory regime and introduction of newer regulations with multiple authorities regulating same areas lead to complexity in compliance. We closely monitor and review our practices to ensure that we remain compliant with relevant laws and legal obligations.

23. SECRETARIAL STANDARDS OF ICSI:

Your Company is in compliance with the Secretarial Standards on Meetings of the Board of Directors (SS-1) and General Meetings (SS-2) issued by The Institute of Company Secretaries of India and approved by the Central Government.

24. DIRECTORS RESPONSIBILITY STATEMENT:

In terms of Section 134 (5) of the Companies Act, 2013 in relation to the Audited Financial Statements of the Company for the year ended March 31, 2026, the Board of Directors hereby confirms that

A. In the preparation of the Financial Statements, for the Financial Year ended March 31, 2026, the applicable Accounting Standards have been followed and that there is no material departures.
B. Appropriate accounting policies have been selected and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company as of March 31, 2026, and of the profit & loss of the Company for the Financial Year ended March 31, 2026.
C. Proper and sufficient care has been taken for maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 2013, for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities.

  1. The Financial Statements have been prepared on a "Going Concern" basis.
  2. Proper Internal Financial Controls were followed by the Company and that such internal financial controls are adequate and were operating effectively.
  3. Proper systems to ensure compliance with the provisions of all applicable laws were in place and that such systems were adequate and operating effectively.

25. OTHER DISCLOSURES

A. DISCLOSURE UNDER SECTION 67 (3) OF THE COMPANIES ACT, 2013:

There were no instances of non-exercising of voting rights in respect of shares purchased directly by employees under a scheme pursuant to Section 67(3) of the Act read with Rule 16(4) of Companies (Share Capital and Debentures) Rules, 2014 is furnished.

B. BUSINESS RESPONSIBILITY AND SUSTAINABILITY REPORT:

In accordance with Regulation 34 of the Listing Regulations, Business Responsibility and Sustainability Report is not applicable to the Company.

C. BANK DEFAULT:

During the period under review, certain dispute cases/notices were received by the Company from various parties including suppliers and lenders in relation to outstanding dues, dishonour of cheque(s), supply transactions and loan repayment obligations. The matters are presently under discussion and are at different stages of resolution.

Further, the Company has defaulted in repayment of its loan obligations to Bank of Maharashtra and Bank of Baroda for a period exceeding 30 days. The above defaults/disputes attracted the disclosure requirements under Regulation 30 read with Clause 6 of Para B of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and the same has been duly disclosed by the Company to the Stock Exchange/s.

26. CAUTIONARY STATEMENT:

The Statements in the Boards Report and the Management Discussion & Analysis describing the Companys objectives, expectations or forecasts may be forward-looking within the meaning of applicable securities laws and regulations. The Actual results may differ materially from those expressed in the statement. Important factors that could influence the Companys operations include input costs, changes in government regulations, tax laws, economic developments within the country and other factors such as litigation and industrial relations.

27. APPRECIATION/ACKNOWLEDGEMENT

Your directors place on records their sincere appreciation for the steadfast commitment and highly motivated performance by the employees at all levels which was instrumental in sustained performance of the Company. The Directors are also grateful and pleased to place on record their appreciation for the assistance and cooperation received from the Financial Institutions, Banks, Government Authorities and Shareholders during the year under review. Your directors are also grateful to the customers, suppliers and business associates of your Company for their continued cooperation and support.

For and on Behalf of the Board of Directors
Sd/- Govardhan Murlidhar Dhoot Chairman & Managing Director DIN: 01240086
Sd/- Brijmohan Murlidhar Dhoot Whole-time Director DIN: 01046420

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2026, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited. All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099

ISO certification icon
We are ISO/IEC 27001:2022 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.